Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derynck

Showing results (251-260 of 260) with videos related to

Pageof 26
Sort By:
You have reached the last page of results.This site can display upto 260 results.
Plos One|April 10, 2009
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on boneKhalid S Mohammad, Carol G Chen, Guive Balooch, et al.
Pediatric Pulmonology|September 30, 2022
Chronic tracheostomy care of ventilator-dependent and -independent children: Clinical practice patterns of pediatric respirologists in a publicly funded (Canadian) healthcare systemAaron St-Laurent, David Zielinski, Adam Qazi, et al.
The Lancet. Oncology|May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trialIan E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsDebashis Sarker, Joo Ern Ang, Richard Baird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast CancerPeter Schmid, Sarah E Pinder, Duncan Wheatley, et al.
Pediatrics|November 23, 2021
Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School AgeTanja Gonska, Katherine Keenan, Jacky Au, et al.
Cell Systems|September 3, 2022
Virtual screening for small-molecule pathway regulators by image-profile matchingMohammad H Rohban, Ashley M Fuller, Ceryl Tan, et al.
Nature Reviews. Molecular Cell Biology|October 16, 2021
Author Correction: Guidelines and definitions for research on epithelial-mesenchymal transitionJing Yang, Parker Antin, Geert Berx, et al.
Nature Reviews. Molecular Cell Biology|April 18, 2020
Guidelines and definitions for research on epithelial-mesenchymal transitionJing Yang, Parker Antin, Geert Berx, et al.
Pageof 26

Showing results (251-260 of 260) with videos related to

Sort By:
Pageof 26
You have reached the last page of results.This site can display upto 260 results.
Plos One|April 10, 2009
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on boneKhalid S Mohammad, Carol G Chen, Guive Balooch, et al.
Pediatric Pulmonology|September 30, 2022
Chronic tracheostomy care of ventilator-dependent and -independent children: Clinical practice patterns of pediatric respirologists in a publicly funded (Canadian) healthcare systemAaron St-Laurent, David Zielinski, Adam Qazi, et al.
The Lancet. Oncology|May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trialIan E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumorsDebashis Sarker, Joo Ern Ang, Richard Baird, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast CancerPeter Schmid, Sarah E Pinder, Duncan Wheatley, et al.
Pediatrics|November 23, 2021
Outcomes of Cystic Fibrosis Screening-Positive Infants With Inconclusive Diagnosis at School AgeTanja Gonska, Katherine Keenan, Jacky Au, et al.
Cell Systems|September 3, 2022
Virtual screening for small-molecule pathway regulators by image-profile matchingMohammad H Rohban, Ashley M Fuller, Ceryl Tan, et al.
Nature Reviews. Molecular Cell Biology|October 16, 2021
Author Correction: Guidelines and definitions for research on epithelial-mesenchymal transitionJing Yang, Parker Antin, Geert Berx, et al.
Nature Reviews. Molecular Cell Biology|April 18, 2020
Guidelines and definitions for research on epithelial-mesenchymal transitionJing Yang, Parker Antin, Geert Berx, et al.
Pageof 26